Gene therapy with p53 tumor suppressor gene in an adenovirus vector: Began three Phase I safety trials, in 21 patients with non-small cell lung cancer and in 27

Introgen Therapeutics Inc., Austin, Texas Product: Gene therapy with p53 tumor suppressor gene in an adenovirus vector Indication: Cancer Status: Began three Phase I safety trials, in 21 patients with...